RGMP
Regnum Corp. [RGMP] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
RGMP Stock Summary
Top 10 Correlated Stocks
RGMP
In the News
RGMP Financial details
Company Rating
-
Market Cap
135.41K
Income
-338.35K
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
1
Optionable
No
Shortable
Yes
Earnings
31 Mar 2023
P/E
-0.26
Forward P/E
-
PEG
-0.09
P/S
-
P/B
-0.1
P/C
-
P/FCF
-0.17
Quick Ratio
0.25
Current Ratio
0.27
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-0.01
EPS next Y
-
EPS next Q
-
EPS this Y
193.1%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
NAN%
Revenue last 5Y
-100%
Revenue Q/Q
-
EPS Q/Q
-
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
-
Inst Trans
-
ROA
-105%
ROE
44%
ROC
0.34%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.0059-0.8
52W High
-
52W Low
-
RSI
100
Rel Volume
0.13
Avg Volume
4.5K
Volume
600
Perf Week
0%
Perf Month
0%
Perf Quarter
0%
Perf Half Y
0%
-
-
-
-
Beta
2.788
-
-
Volatility
0%, 0%
Prev Close
0%
Price
0.0001
Change
0%
Company Profile
- Volume Average 4.5K
- Market Capitalization 135.41K
- Employee 1
- CEO Mr. Robert J. Stubblefield CPA
- Headquarters New York,NY,US
- IPO Date 2019-05-29
Regnum Corp. develops and commercializes therapeutics that treat rare and infectious diseases. It develops Leronlimab (PRO 140), a monoclonal antibody CC chemokine receptor type 5 antagonist, that is designed to prevent human immunodeficiency virus from entering human cells. The company is based in New York, New York. Regnum Corp. is a subsidiary of Phoenixus AG.
